Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Oct 19, 2021 10:00 AM - Oct 20, 2021 5:00 PM

(US Eastern Standard Time)

DIA Canadian Annual Meeting

The Canadian Annual Meeting now includes a track for Pharmacovigilence and Risk Management Strategies!

Session 6 Track B: Real-World Data and Real-World Evidence

Session Chair(s)

Judith  Mergl, MSc

Judith Mergl, MSc

Head of Regulatory Affairs and Operational Services, Canada

AbbVie Corporation, Canada

In a market that is constantly adapting and adjusting to healthcare needs, real-world evidence (RWE) is increasingly becoming important for regulatory and reimbursement decision-making. RWE, in relation to the real-world data that is collected in combination with the advancement of artificial intelligence-based analytics platforms, has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions. RWE is now becoming integrated throughout the product development lifecycle, and this session will explore new and innovative applications of RWE and provide insights through case examples and practical applications on how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making. This session will provide a high-level overview of the evolving regulatory landscape for RWD/RWE from a Health Canada, CADTH, and industry perspective.

Learning Objective :
  • Gain a greater awareness of Health Canada’s international collaborations in the COVID-19 space that are leveraging RWE and observational studies
  • Provide an overview of premarket challenges with RWE as well as a high-level overview on details and limitations regarding some recent examples submitted by sponsors in the premarket setting
  • Discuss “lessons learned” from current uses of RWE, and how these can be applied for other future HTA applications

Speaker(s)

Melissa  Kampman, PhD, MS

Post-Market Utilization of RWE at Health Canada: Progress to Date and International Collaborations Leveraging RWE for COVID-19

Melissa Kampman, PhD, MS

Health Canada, Canada

Manager and Senior Epidemiologist, Marketed Health Products Directorate

Andrew  Raven, MSc

Premarket RWE Examples and Challenges: Regulatory Perspective

Andrew Raven, MSc

Health Canada, Canada

Manager for Biostatistics, Epidemiology, and Pharmacometrics Unit, HPFB

Nicole  Mittmann, MSc

Speaker

Nicole Mittmann, MSc

Canadian Agency for Drugs and Technologies in Health (CADTH), Canada

Chief Scientist and Vice President of Evidence Standards

Yonghua  Jing, PhD, MS

Speaker

Yonghua Jing, PhD, MS

AbbVie, United States

Senior Director/Team Lead, Real-World Evidence Analytics

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.